LeMaitre Vascular, Inc. (LMAT) AI Stock Analysis

LeMaitre Vascular, Inc. is a medical device company that designs, markets, sells, services, and supports devices and implants used in the treatment of peripheral vascular disease. Its product portfolio includes angioscopes for viewing blood vessel lumens, embolectomy catheters for removing blood clots, occlusion catheters, and perfusion catheters. The company also offers thrombectomy catheters, carotid shunts used in endarterectomy surgeries, radiopaque tape, valvulotomes for disrupting vein valves, vascular grafts, and vascular and cardiac patches. Additionally, it produces closure systems using titanium clips to replace sutures, distributing products through direct sales teams and global distributors.

Revenue grew at a 5-year CAGR of 14.0% from FY2020 to FY2025, expanding from $154.4M in FY2021 to $249.6M in FY2025. Annual revenue growth reached 19.4% in FY2021, 4.7% in FY2022, 19.7% in FY2023, 13.6% in FY2024, and 13.5% in FY2025. Gross margin expanded from 65.7% in FY2021 to 71.5% in FY2025, while operating margin rose from 23.6% to 27.2%. Net income increased from $26.9M in FY2021 to $57.7M in FY2025, lifting diluted EPS to $2.51. In the latest quarter ended June 30, 2026, quarterly revenue grew 9.6% year-over-year, and quarterly earnings grew 22.6%, contributing to trailing twelve months revenue of $262.4M and EPS of $2.85.

As of June 30, 2026, LeMaitre Vascular held $376.2M in cash and short-term investments against total debt of $190.3M, resulting in net cash of $186.0M. Shareholders' equity was $420.3M against total assets of $640.5M, with a current ratio of 16.31 and a debt-to-equity ratio of 0.45. Operating cash flow in FY2025 was $81.3M, generating free cash flow of $74.5M after capital expenditures of $6.8M. Cash was also deployed toward $18.1M in dividends paid during FY2025, while the share count increased 10.8% over five years.

At a share price of $80.82, LeMaitre Vascular trades at a trailing P/E of 28.4x and a forward P/E of 25.6x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its enterprise value of $1.66B implies an EV/EBITDA of 16.5x and EV/revenue of 6.3x, above the peer medians of 12.0x and 4.1x for price-to-sales, where LMAT trades at 7.0x. Over the past year, the stock fell 6.0%, trailing the S&P 500 return of 16.8%. Over five years, its return of 58.2% lagged the S&P 500 return of 83.0%.

LeMaitre Vascular pays a quarterly dividend with a forward annual rate of $1.00 per share, yielding 1.24%. The dividend payout ratio stands at 33.3%. The company has paid dividends for 16 consecutive years, generating a 5-year annualized dividend growth rate of 16.1%. Its most recent ex-dividend date was August 20, 2026.

Wall Street analyst sentiment includes 2 Strong Buy, 2 Buy, and 4 Hold ratings, with 0 Sell and 0 Strong Sell ratings. The mean price target of $107.00 represents 32.4% upside over the last close of $80.82. For the current fiscal year ending December 31, 2026, consensus estimates project EPS of $2.88, representing 14.2% growth, on revenue of $276.5M. For the next fiscal year, 8 analysts project revenue of $302.9M and EPS of $3.18. The company beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of LeMaitre Vascular, Inc. (LMAT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LMAT income statement, LMAT balance sheet, LMAT key metrics, LMAT analyst forecast, LMAT chart. See the LMAT stock overview for the latest quote and news.